The Cigna Group (CI) Revenue by Segment

Cigna Group revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Cigna Group's largest business segment was Evernorth, with $61.47 billion or 84% of revenue, up 6.3% from a year earlier. Next: Cigna Healthcare (16%) and All other segments (under 1%).

By product or service, Product brought in 93% and Service brought in 7% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Cigna Healthcare (+9.6%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2018.

The Cigna Group

CIHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

EvernorthCigna HealthcareHealth ServicesIntegrated MedicalU.S. MedicalInternational MarketsGroup Disability and OtherOther OperationsOther

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Evernorth	USD 61.47B	83.7%	+6.3%
Cigna Healthcare	USD 11.84B	16.1%	+9.6%
All other segments	USD 131.00M	0.2%	-28.8%
Corporate and Eliminationsi	-USD 1.77B		–

Sum of items USD 73.44B; corporate items and eliminations -USD 1.77B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18
Evernorth	61.5B	58.4B	63.1B	60.4B	57.8B	53.7B	53.7B	51.6B	49.5B	46.2B	40.5B	38.6B	38.2B	36.2B	36.2B	35.7B	34.9B	33.6B	35.1B	33.6B	32.6B	30.6B	–	29.9B	28.6B	27.3B	–	–	–	–	–	–	–	–
Cigna Healthcare	11.8B	11.5B	11.1B	10.9B	10.8B	14.5B	13.3B	11.9B	13.2B	13.3B	13.0B	12.7B	12.7B	12.8B	11.1B	11.1B	11.4B	11.3B	11.2B	11.2B	11.2B	11.1B	–	–	–	–	–	–	–	–	–	–	–	–
Health Services	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	27.6B	28.0B	26.9B	3.8B	1.1B	1.1B	1.1B
Integrated Medical	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	9.1B	9.0B	9.2B	8.3B	8.2B	8.2B	8.2B
U.S. Medical	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	9.6B	9.2B	9.9B	–	–	–	–	–	–	–	–
International Markets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.5B	1.5B	1.5B	–	1.4B	1.4B	1.4B	1.3B	1.3B	1.3B	1.3B
Group Disability and Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.3B	1.3B	1.3B	–	1.3B	1.3B	1.3B	1.2B	1.3B	1.3B	1.3B
Other Operations	–	–	–	–	–	–	–	–	–	–	134.0M	–	–	157.0M	182.0M	153.0M	948.0M	979.0M	994.0M	1.0B	990.0M	1.0B	–	–	–	–	–	–	–	–	–	–	–	–
All other segments	131.0M	120.0M	153.0M	162.0M	184.0M	175.0M	201.0M	137.0M	227.0M	166.0M	–	147.0M	158.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Cigna Group revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Evernorth	$61.5B	$58.4B	$60.4B	$57.8B	84%
Cigna Healthcare	$11.8B	$11.5B	$10.9B	$10.8B	16%
All other segments	$131.0M	$120.0M	$162.0M	$184.0M	under 1%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Cigna Group revenue by product or service, last 4 quarters

Product or service	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Product	$57.2B	$54.0B	$56.1B	$53.6B	93%
Service	$4.4B	$4.4B	$4.4B	$4.1B	7%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Cigna Group's business segments?

Evernorth, Cigna Healthcare and All other segments (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Cigna Group?

Evernorth: $61.47 billion, or 84% of revenue, in Q2 fiscal 2026.

What are Cigna Group's main products and services?

By revenue in Q2 fiscal 2026: Product (93%) and Service (7%).

MoreCigna Group stock overview Cigna Group financials Cigna Group executive team Cigna Group shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.